Patrick J Brown1, Adam Ciarleglio2, Steven P Roose3, Carolina Montes Garcia3, Sarah Chung4, Johana Alvarez3, Alexandra Stein3, Stephanie Gomez3, Bret R Rutherford3. 1. New York State Psychiatric Institute, Columbia University College of Physicians and Surgeons (PJB, SPR, CMG, JA, AS, SG, BRR), New York, NY. Electronic address: pb2410@cumc.columbia.edu. 2. Department of Biostatistics and Bioinformatics, Milken Institute School of Public Health, George Washington University (AC), Washington, DC. 3. New York State Psychiatric Institute, Columbia University College of Physicians and Surgeons (PJB, SPR, CMG, JA, AS, SG, BRR), New York, NY. 4. Albert Einstein College of Medicine (SC), New York, NY.
Abstract
OBJECTIVE: To investigate the relationship between frailty and treatment response to antidepressant medications in adults with late life depression (LLD). METHODS: Data were evaluated from 100 individuals over age 60 years (34 men, 66 women) with a depressive diagnosis, who were assessed for frailty at baseline (characteristics include gait speed, grip strength, activity levels, fatigue, and weight loss) and enrolled in an 8-week trial of antidepressant medication followed by 10 months of open-treatment. RESULTS: Frail individuals (n = 49 with ≥3 deficits in frailty characteristics) did not differ at baseline from the non/intermediate frail (n = 51 with 0-2 deficits) on demographic, medical comorbidity, cognitive, or depression variables. On average, frail individuals experienced 2.82 fewer Hamilton Rating Scale for Depression (HRSD) points of improvement (t = 2.12, df 89, p = 0.037) than the non/intermediate frail over acute treatment, with this difference persisting over 10 months of open-treatment. Weak grip strength and low physical activity levels were each associated with decreased HRSD improvement, and lower response and remission rates over the course of the study. Despite their poorer outcomes, frail individuals received more antidepressant medication trials than the non/intermediate frail. CONCLUSION: Adults with LLD and frailty have an attenuated response to antidepressant medication and a greater degree of disability compared to non/intermediate frail individuals. This disability and attenuated response remain even after receiving a greater number of antidepressant medication trials. Future research must focus on understanding the specific pathophysiology associated with the frail-depressed phenotype to permit the design and implementation of precision medicine interventions for this high-risk population.
OBJECTIVE: To investigate the relationship between frailty and treatment response to antidepressant medications in adults with late life depression (LLD). METHODS: Data were evaluated from 100 individuals over age 60 years (34 men, 66 women) with a depressive diagnosis, who were assessed for frailty at baseline (characteristics include gait speed, grip strength, activity levels, fatigue, and weight loss) and enrolled in an 8-week trial of antidepressant medication followed by 10 months of open-treatment. RESULTS: Frail individuals (n = 49 with ≥3 deficits in frailty characteristics) did not differ at baseline from the non/intermediate frail (n = 51 with 0-2 deficits) on demographic, medical comorbidity, cognitive, or depression variables. On average, frail individuals experienced 2.82 fewer Hamilton Rating Scale for Depression (HRSD) points of improvement (t = 2.12, df 89, p = 0.037) than the non/intermediate frail over acute treatment, with this difference persisting over 10 months of open-treatment. Weak grip strength and low physical activity levels were each associated with decreased HRSD improvement, and lower response and remission rates over the course of the study. Despite their poorer outcomes, frail individuals received more antidepressant medication trials than the non/intermediate frail. CONCLUSION: Adults with LLD and frailty have an attenuated response to antidepressant medication and a greater degree of disability compared to non/intermediate frail individuals. This disability and attenuated response remain even after receiving a greater number of antidepressant medication trials. Future research must focus on understanding the specific pathophysiology associated with the frail-depressed phenotype to permit the design and implementation of precision medicine interventions for this high-risk population.
Authors: Pinar Soysal; Nicola Veronese; Trevor Thompson; Kai G Kahl; Brisa S Fernandes; A Matthew Prina; Marco Solmi; Patricia Schofield; Ai Koyanagi; Ping-Tao Tseng; Pao-Yao Lin; Che-Sheng Chu; Theodore D Cosco; Matteo Cesari; Andre F Carvalho; Brendon Stubbs Journal: Ageing Res Rev Date: 2017-03-31 Impact factor: 10.895
Authors: Patrick J Brown; Steven P Roose; Kaleigh R O'Boyle; Adam Ciarleglio; Benjamin Maas; Kay C Igwe; Sarah Chung; Stephanie Gomez; Maleeha Naqvi; Adam M Brickman; Bret R Rutherford Journal: Am J Geriatr Psychiatry Date: 2019-10-14 Impact factor: 4.105
Authors: A John Rush; Diane Warden; Stephen R Wisniewski; Maurizio Fava; Madhukar H Trivedi; Bradley N Gaynes; Andrew A Nierenberg Journal: CNS Drugs Date: 2009-08 Impact factor: 5.749
Authors: Charles L Raison; Robin E Rutherford; Bobbi J Woolwine; Chen Shuo; Pamela Schettler; Daniel F Drake; Ebrahim Haroon; Andrew H Miller Journal: JAMA Psychiatry Date: 2013-01 Impact factor: 21.596
Authors: Joel R Sneed; Michelle E Culang; John G Keilp; Bret R Rutherford; Davangere P Devanand; Steven P Roose Journal: Am J Geriatr Psychiatry Date: 2010-02 Impact factor: 4.105
Authors: Patrick J Brown; Steven P Roose; Robert Fieo; Xinhua Liu; Taina Rantanen; Joel R Sneed; Bret R Rutherford; D P Devanand; Kirsten Avlund Journal: Am J Geriatr Psychiatry Date: 2013-08-20 Impact factor: 4.105
Authors: Yi Deng; Douglas R McQuoid; Guy G Potter; David C Steffens; Kimberly Albert; Meghan Riddle; John L Beyer; Warren D Taylor Journal: Depress Anxiety Date: 2018-05-10 Impact factor: 6.505
Authors: Renata M Sousa; Michael E Dewey; Daisy Acosta; A T Jotheeswaran; Erico Castro-Costa; Cleusa P Ferri; Mariella Guerra; Yueqin Huang; K S Jacob; Juana Guillermina Rodriguez Pichardo; Nayeli Garcia Ramírez; Juan Llibre Rodriguez; Marina Calvo Rodriguez; Aquiles Salas; Ana Luisa Sosa; Joseph Williams; Martin J Prince Journal: Int J Methods Psychiatr Res Date: 2010-03 Impact factor: 4.035
Authors: Ivan Aprahamian; Marcus K Borges; Denise J C Hanssen; Hans W Jeuring; Richard C Oude Voshaar Journal: Clin Interv Aging Date: 2022-06-22 Impact factor: 3.829
Authors: Patrick J Brown; Adam Ciarleglio; Steven P Roose; Carolina Montes Garcia; Sarah Chung; Sara Fernandes; Bret R Rutherford Journal: J Gerontol A Biol Sci Med Sci Date: 2022-05-05 Impact factor: 6.591